Navigation Links
Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
Date:9/30/2010

settled on October 12, 2010.

In addition, warrant holders of Movetis have agreed to tender 727,911 new shares to be issued on the settlement date following the conditional exercise of warrants.

Accordingly, Shire Holdings Luxembourg S.a r.l. (a subsidiary of Shire plc) will own 99.21% of the outstanding shares of Movetis on the settlement date of the tender offer.

Squeeze-Out Procedure

Shire has decided to proceed with a squeeze-out of those shares not tendered to the offer in accordance with applicable Belgian legislation. In this regard, an additional tender offer period will open, on the same terms, on October 12, 2010 and close on November 2, 2010 at 4 pm CET.

Shares tendered into the additional tender offer are expected to be settled on November 8, 2010. Shares and warrants not tendered to the additional tender offer shall be deemed transferred to Shire Holdings Luxembourg S.a r.l. by operation of law on November 8, 2010. Payment of the offer price for shares and warrants not tendered to the additional tender offer will be deposited with the Deposito-en Consignatiekas/Caisse des Depots et Consignations in Belgium.

At the close of the reopened tender offer, the shares in Movetis will be delisted from Euronext Brussels. The last trading day will therefore be November 2, 2010.

Shire's offer is EUR19 in cash for each outstanding Movetis share.

The prospectus relating to the tender offer and the squeeze-out is available at no cost at the counters of the Receiving and Paying Agents in Belgium The Royal Bank of Scotland N.V. or by phone (+3120/4643707), KBC Securities NV, KBC Bank NV, CBC Banque SA or by phone 03/283 29 70 (KBC telecenter) or 0800/92 020 (CBC Banque). An electronic version of the prospectus is available on the following websites: http://www.kbcsecurities.be, http://www.kbc.be, http
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Shire Announces Holding of 81% in Jerini AG and Publication of Offer Document
2. Change of Name to Shire plc
3. Shires New Product Portfolio Delivers Strong Quarterly Performance
4. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
5. Shire plc: Change to Directors Details
6. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
7. Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion
8. Shire to Enter European ADHD Market With the Acquisition of EQUASYM(R) IR and XL
9. Shire Announces Opening of Office in Japan
10. Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
11. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... August 20, 2014 One of ... medicine is an inadequate vascular supply. Nutrient and ... decellularized tissues is critical for successful regeneration and ... to mitigate deficiencies in vascularization and promote angiogenesis ... bioactivity, optimizing scaffold design and architecture, and enhancing ...
(Date:8/19/2014)... Cellgen Diagnostics today ... fund a corporate lab for its genetic-based medical ... is a critical component in the move from ... implementation of personalized medicine – a more predictive, ... Indiegogo contributions will support Cellgen’s intent to develop ...
(Date:8/19/2014)... 19, 2014 Research and ... the "Spectroscopy Equipment and Accessories - ... their offering. This report ... and Accessories in US$ Thousands by the ... Raman Spectrometers, NMR-EPR Spectrometers, Near Infrared (NIR) ...
(Date:8/19/2014)... Aug. 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" ... reported results of its Oral Amphotericin B (Oral ... The study, conducted by ImmuneCarta®, the immune monitoring ... effectiveness of Oral Amp B in reactivating ... individuals despite intensive treatment with antiretroviral therapy. ...
Breaking Biology Technology:Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3
... to present at 2008 BIO CEO & Investor conference at ... New York on Tuesday, February 12 at 1:15 PM (Eastern), ... -- James A. Bianco, M.D., President and CEO of Cell,Therapeutics, ... overview of,the Company,s sales and marketing strategy intended to grow ...
... eResearchTechnology,Inc. (eRT), (Nasdaq: ERES ), ... and interpretation services including,expert consultation and a ... capture and electronic patient reported outcomes,solutions), announced ... fourth quarter,results for the period ended December ...
... CHICAGO, Feb. 11 Advanced Life Sciences,Holdings, Inc. ... in the,discovery, development and commercialization of novel drugs ... diseases today,announced that it will host a conference ... and full-year financial results on Tuesday,February 19 at ...
Cached Biology Technology:Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008 2Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008 3Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008 4Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008 5eResearchTechnology, Inc. to Announce 2007 Fourth Quarter Results on February 26, 2008 2Advanced Life Sciences To Host 2008 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast 2Advanced Life Sciences To Host 2008 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast 3
(Date:8/19/2014)... German . , , ... of plants can switch off individual genes and study ... Planck Institute for Plant Breeding Research in Cologne and ... different approach. They identify small molecules that block specific ... prevent the downstream reactions. In their search for these ...
(Date:8/19/2014)... young have bigger brains than counterparts that don,t care ... study. , Stickleback fish are well known in the ... the species, rather than the female, cares for offspring. ... researchers wanted to find out if the difference in ... , In the study, published recently in Ecology ...
(Date:8/18/2014)... Ariz. Half of the Earth,s land mass is ... yet they are being transformed at an alarming rate. ... in and taking over, leading to a loss of ... ability of ecosystems to produce food specifically meat. ... Life Sciences led an investigation that quantified this loss ...
Breaking Biology News(10 mins):Researchers block plant hormone 2Researchers block plant hormone 3Trees and shrubs invading critical grasslands, diminish cattle production 2Trees and shrubs invading critical grasslands, diminish cattle production 3
... N.Y. Proteins are critically important to life and the ... in nature, and there is much we still don,t know ... the stability of enzymes, a particular type of protein that ... natural environment in the cell or body, enzymes can quickly ...
... that nanoparticles, which are now present in everything from ... irreparably damaging effects on soil systems and the environment. ... every year, including silver nanoparticles which are popular as ... Department of Biology. "We started to wonder what the ...
... (April 6, 2011) -- A new drug delivery device ... Peter Rentzepis promises to unlock the potential of photosensitive ... as well. Photosensitive chemicals are molecules that ... These radicals are very active chemically, and can rip ...
Cached Biology News:Nano fit-ness: Helping enzymes stay active and keep in shape 2Common nanoparticles found to be highly toxic to Arctic ecosystem 2New device promises safer way to deliver powerful drugs 2
RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Mouse monoclonal to Factor V Heavy Chain Immunogen: Purified human Factor V. Specificity: This antibody reacts with the activation C peptide (mw ~150,000) in the heavy chain of thrombin-cleave...
... polyclonal to MSY2/YBOX2 ( Abpromise ... Antigen: Synthetic peptide derived ... C-terminus of Human MSY2/YBOX2. (Note: ... (Peptide available as ...
... Immunogen: Peptide corresponding ... human, mouse, and rat phospho-FAK (Ser843) ... NM_153831 Quality ... Molecular Weight: ...
Biology Products: